Abstract
Ulcerative colitis (UC) is a chronic relapsing remitting inflammatory disease of the colon. The lifetime risk of presentation with acute severe ulcerative colitis (ASUC) is 15%.1 Patients with ASUC receive first line therapy with intravenous corticosteroids, however, approximately 30% have corticosteroid-refractory disease.2,3 In this situation, rescue medical therapy options include the anti-tumor necrosis factor (TNF) monoclonal antibody infliximab (IFX) or the calcineurin inhibitor ciclosporin.2 A significant proportion of patients fail to respond to IFX therapy with reported colectomy rates at 1 year of 35%.4 Biomarkers which identify patients with corticosteroid-refractory ASUC, with a reduced likelihood of IFX response, would significantly advance clinical care for these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 381-385 |
| Journal | Intestinal Research |
| Volume | 20 |
| Issue number | 3 |
| Early online date | 31 Dec 2022 |
| DOIs | |
| Publication status | Published - 31 Dec 2022 |
Fingerprint
Dive into the research topics of 'Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver